Pressure is mounting on the federal government to subsidise weight loss medications through the Pharmaceutical Benefits Scheme, with Health Minister Mark Butler publicly backing the push after costs as high as $600 a month — or $150 a week — left hundreds of thousands of Australians paying out of pocket for treatments he describes as "revolutionary".
Speaking on Monday, Butler confirmed negotiations with pharmaceutical companies over pricing remain the central obstacle to a PBS listing, but said the matter was too significant to leave unresolved.
Weight Loss Drugs 'Out of Reach' for Too Many Australians
An estimated 600,000 Australians are currently accessing weight loss medications through the private market, spending anywhere between $5,000 and $6,000 a year to do so. Butler was unequivocal about the inequity that creates.
"This is a revolutionary class of drugs, and I certainly want to see them on the PBS so that Australians have access to them in an equitable way," he said. "It's way out of reach of far too many Australians."
The independent experts who advise on PBS listings have already put forward a recommendation, though it is relatively narrow in scope — covering people with a body mass index (BMI) of 35 or above who also have established cardiovascular disease.
Butler indicated the government supports a broader ambition for access but acknowledged that a price agreement with the two companies currently supplying these drugs to the Australian market has not yet been reached.
"We haven't been able to agree that price yet but we've got to get there," he said. "This is too important a class of drugs not to have on the PBS. There are too many benefits for too many Australians to have it available only to those who are able to find $5,000 or $6,000 a year for it."
Global Drug Market Pressures Complicating Negotiations
The pricing talks are not happening in isolation. Butler noted that broader turbulence in global medicines markets — driven in part by policy decisions in the United States — is affecting Australia's ability to secure favourable pricing not just for weight loss drugs, but also for treatments for conditions including multiple sclerosis and breast cancer.
The minister said he had made Australia's position clear directly to the pharmaceutical companies involved, as well as to his own department, signalling that securing a PBS listing is a firm government priority rather than a distant aspiration.
Bulk Billing Rates Also on the Rise
Monday's announcement on weight loss drugs came alongside encouraging news on another front of healthcare affordability, with new government figures showing bulk billing rates climbing from 81.9 per cent to 84.1 per cent nationally in the June quarter.
New South Wales and Victoria lead the country, with both states recording bulk billing rates above 85 per cent. The Northern Territory recorded a striking annual increase of 13 per cent, while the ACT continued to lag significantly behind the rest of the country at just 59.3 per cent.
Butler said the improvement meant millions more free GP visits for Australians this year, with pensioners seeing bulk billing rates climb back above 90 per cent.
"It means that people are going to the doctor when they need to, rather than when they feel they can find the $50 or $60 to pay the gap fee," he said.
Australians without concession cards have also benefited, with their bulk billing rates rising by more than 10 per cent since last October. Several regions — including the Illawarra, Northern Territory, Northern Tasmania and Bendigo — have recorded increases of between 20 and 30 per cent.
"Turning around bulk billing is not just a great cost-of-living measure... we know it is leading to better health and building a healthier Australia," Butler said.
What Comes Next on PBS Weight Loss Drug Listing
With pricing negotiations still ongoing, there is no confirmed timeline for when weight loss drugs might appear on the PBS. However, Butler's language on Monday was among the strongest yet from a senior government figure — framing a subsidised listing not as a possibility but as a necessity, and indicating that the government intends to keep pushing pharmaceutical companies until a deal is done.
For the hundreds of thousands of Australians currently shouldering the full cost themselves, the outcome of those negotiations could prove life-changing.
